lundi 10 décembre 2018

Onco Actu du 10 décembre 2018

3.8 Prévention - Alimentation

It’s Time to Study Whether Eating Particular Diets Can Help Heal Us [NY Times]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

FDA guide unveils vision for cancer diagnostics [Biopharma Dive]

FDA Drafts Guidance on Oncology Companion Diagnostics [RAPS]

4.3 Dép., diag. & prono. - Industriels

QIAGEN announces new collaboration to develop companion diagnostic to guide treatment for patients with PIK3CA-mutated advanced breast cancer [Quiagen]

4.5 Dép., diag. & prono. - Colorectal

Don't take my colonoscopy away! [UW Medicine]

Older adults may be unwilling to give up colorectal screening [Reuters]

4.7 Dép., diag. & prono. - Col de l'utérus

HPV type 16 or 18 in young women predicts risk of cervical cancer [Karolinska Institutet]

5. Traitements

More than 260 new drugs to treat cancer? [Anticancer Fund]

ReDO_DB: the repurposing drugs in oncology database [ecancer Medical Science]

5.10 Traitements - Essais

Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival [NCI]

5.12.1 Immunothérapies - partenariats

Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers [BMS]

5.12.5 Immunothérapies - Pharma

AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer [FiercePharma]

5.12.6 Immunothérapies - AMM

Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck [FiercePharma]

Roche's Tecentriq gets first-line lung cancer approval [Biopharma Dive]

Delay brings success for Roche as it finally wins FDA nod for Tecentriq regimen in frontline lung cancer [EndPoints]

5.2.1 Pharma - Partenariats

AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines [AstraZeneca]

5.2.2 Pharma - Fusions & Acquisitions

With Tesaro off the block, will Clovis be the next PARP maker to get swallowed up? [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

FDA will allow observational studies as part of a push for real world evidence, new framework says [EndPoints]

5.7.2 SABCS-divers

EndoPredict is the Only Test to Answer Three Critical Questions [Myriad]

Novartis sheds light on liquid biopsies with SOLAR-1 analysis [Biopharma Dive]

New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment [Agendia]


Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors [AACR]

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors [AACR]

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates [AACR]

Exercise Performed During Adjuvant Breast Cancer Treatment May Improve Cardiovascular Function [AACR]

5.7.4 SABCS-essais

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease [Novartis]

6. Lutte contre les cancers

Encouraging Edge Science through NIH Funding Practices [Stanford]

6.1 Observation

Breast cancer survivors may have lingering mental health effects [Reuters]

6.10.1 Politiques (USA)

Despite growing budget, U.S. cancer institute slashes operating budget by 5% [Science]

6.12 Ethique

What These Medical Journals Don’t Reveal: Top Doctors’ Ties to Industry [NY Times]

He Jiankui’s Genetic Misadventure: Why Him? Why China? [Hastings Center]